Posted inApps Editors Pick Gadget
AstraZeneca stock jumps 4% after surprise lung disease trial win
AstraZeneca's stock jumped as much as 4% after Britain's most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment Tozorakimab,…






